These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 23872476)

  • 1. Evidence for a role of CETP in HDL remodeling and cholesterol efflux: role of cysteine 13 of CETP.
    Maugeais C; Perez A; von der Mark E; Magg C; Pflieger P; Niesor EJ
    Biochim Biophys Acta; 2013 Nov; 1831(11):1644-50. PubMed ID: 23872476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.
    Niesor EJ; Magg C; Ogawa N; Okamoto H; von der Mark E; Matile H; Schmid G; Clerc RG; Chaput E; Blum-Kaelin D; Huber W; Thoma R; Pflieger P; Kakutani M; Takahashi D; Dernick G; Maugeais C
    J Lipid Res; 2010 Dec; 51(12):3443-54. PubMed ID: 20861162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
    Niesor EJ
    Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
    Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG
    Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholesteryl ester transfer between lipoproteins does not require a ternary tunnel complex with CETP.
    Lauer ME; Graff-Meyer A; Rufer AC; Maugeais C; von der Mark E; Matile H; D'Arcy B; Magg C; Ringler P; Müller SA; Scherer S; Dernick G; Thoma R; Hennig M; Niesor EJ; Stahlberg H
    J Struct Biol; 2016 May; 194(2):191-8. PubMed ID: 26876146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib.
    Johns DG; Chen Y; Wang SP; Castro-Perez J; Previs SF; Roddy TP
    Eur J Pharmacol; 2015 Sep; 762():256-62. PubMed ID: 26049012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study.
    Ballantyne CM; Miller M; Niesor EJ; Burgess T; Kallend D; Stein EA
    Am Heart J; 2012 Mar; 163(3):515-21, 521.e1-3. PubMed ID: 22424025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial.
    Ray KK; Ditmarsch M; Kallend D; Niesor EJ; Suchankova G; Upmanyu R; Anzures-Cabrera J; Lehnert V; Pauly-Evers M; Holme I; Štásek J; van Hessen MW; Jones P;
    Eur Heart J; 2014 Jul; 35(27):1792-800. PubMed ID: 24639426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
    Mohammadpour AH; Akhlaghi F
    Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re-evaluation of cholesteryl ester transfer protein function in atherosclerosis based upon genetics and pharmacological manipulation.
    Yamashita S; Matsuzawa Y
    Curr Opin Lipidol; 2016 Oct; 27(5):459-72. PubMed ID: 27454452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of enhanced cholesteryl ester transfer from high density lipoproteins to apolipoprotein B-containing lipoproteins during alimentary lipemia.
    Tall A; Sammett D; Granot E
    J Clin Invest; 1986 Apr; 77(4):1163-72. PubMed ID: 3958185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aerobic exercise improves reverse cholesterol transport in cholesteryl ester transfer protein transgenic mice.
    Rocco DD; Okuda LS; Pinto RS; Ferreira FD; Kubo SK; Nakandakare ER; Quintão EC; Catanozi S; Passarelli M
    Lipids; 2011 Jul; 46(7):617-25. PubMed ID: 21479674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesteryl ester diffusion, location and self-association constraints determine CETP activity with discoidal HDL: excimer probe study.
    Dergunov AD; Shabrova EV; Dobretsov GE
    Arch Biochem Biophys; 2014 Dec; 564():211-8. PubMed ID: 25449063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport.
    Tchoua U; D'Souza W; Mukhamedova N; Blum D; Niesor E; Mizrahi J; Maugeais C; Sviridov D
    Cardiovasc Res; 2008 Mar; 77(4):732-9. PubMed ID: 18056760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.
    Yamashita S; Ruscica M; Macchi C; Corsini A; Matsuzawa Y; Sirtori CR
    Atherosclerosis; 2018 Nov; 278():286-298. PubMed ID: 30347344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein.
    de Vries-van der Weij J; de Haan W; Hu L; Kuif M; Oei HL; van der Hoorn JW; Havekes LM; Princen HM; Romijn JA; Smit JW; Rensen PC
    Endocrinology; 2009 May; 150(5):2368-75. PubMed ID: 19147676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
    Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
    Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein A-II is a key regulatory factor of HDL metabolism as appears from studies with transgenic animals and clinical outcomes.
    Maïga SF; Kalopissis AD; Chabert M
    Biochimie; 2014 Jan; 96():56-66. PubMed ID: 24012775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses.
    van Capelleveen JC; Kastelein JJ; Zwinderman AH; van Deventer SJ; Collins HL; Adelman SJ; Round P; Ford J; Rader DJ; Hovingh GK
    J Clin Lipidol; 2016; 10(5):1137-1144.e3. PubMed ID: 27678430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
    Nurmohamed NS; Ditmarsch M; Kastelein JJP
    Cardiovasc Res; 2022 Nov; 118(14):2919-2931. PubMed ID: 34849601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.